VIRUS
STRUCTURE · SPREAD
COURSE
CLUE
Picornavirus, ssRNA; fecal-oral (travel, shellfish, daycare)
Acute, self-limited; no carrier state; rarely fulminant
IgM anti-HAV = acute · vaccine
Hepadnavirus, partially dsDNA, replicates by reverse transcriptase; blood, sex, perinatal
Chronic in ~90% of neonates, < 5% of adults
HCC even without cirrhosis (DNA integration)
Hepatitis B — extrahepatic
Immune complexes containing HBsAg
Polyarteritis nodosa, membranous nephropathy, serum sickness-like prodrome (rash, arthralgia)
Ground-glass hepatocytes (HBsAg)
Suppress replication
Tenofovir, entecavir (nucleos(t)ide analogs); peginterferon-α
Vaccine (recombinant HBsAg) → anti-HBs only
Flavivirus, ssRNA, no proofreading (antigenic variation); IV drug use, transfusion before 1992
Chronic in most (~75%) → cirrhosis, HCC; often silent
Anti-HCV antibody, confirm with HCV RNA · no vaccine
Hepatitis C — extrahepatic
B-cell stimulation, immune complexes
Mixed cryoglobulinemia, MPGN, porphyria cutanea tarda, lichen planus, B-cell lymphoma, insulin resistance
Purpura + arthralgia + low complement
Direct-acting antivirals
NS5B polymerase inhibitor (sofosbuvir) + NS5A inhibitor (ledipasvir, velpatasvir) or NS3/4A protease inhibitor (glecaprevir)
Cure rates > 95%
Defective RNA virus; needs HBsAg for its envelope
Coinfection (with acute HBV) or superinfection of chronic HBV (worse, fulminant)
HBV vaccine prevents HDV
Hepevirus, ssRNA; fecal-oral, contaminated water, undercooked pork
Usually acute; fulminant in pregnant women; chronic in transplant patients
Outbreaks in South Asia, Africa
Cytotoxic T cells kill infected hepatocytes
Acute: ballooning, Councilman bodies (apoptosis), lobular inflammation · chronic: portal inflammation, interface hepatitis, fibrosis
HCV: lymphoid aggregates + steatosis